Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Dosage
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Dosage

2 evidence topics · 2 sources

Investigational acute-flare doses in GEMINI-1

“750mg IV imsidolimab, 300mg IV imsidolimab or placebo” (opens the source at this quote in a new tab)

Investigational regimen in GALLOP

“750mg IV dose of imsidolimab” (opens the source at this quote in a new tab)
“monthly 100mg subcutaneous dose of imsidolimab beginning at Week 4 and continued through Week 12.” (opens the source at this quote in a new tab)